gastric cancer
Conditions
Interventions
Adenocarcinoma of the esophagogastric junction underwent neoadjuvant treatment and then received robotic radical total gastrectomy group:NA
Laparoscopic radical total gastrectomy was performed after neoadjuvant therapy for adenocarcinoma of the esophagogastric junction group:NA
Sponsors
The First Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age >18 years old, <75 years old; 2.Pathologically confirmed as adenocarcinoma of the esophagogastric junction (Siewert II and III types), the pathological types include papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, and signet ring cell carcinoma; 3.Before neoadjuvant therapy, the clinical stage was confirmed as cII-cIII (cT2N+M0, cT3-4aN0/+M0) by gastroscopy + endoscopic ultrasound, enhanced CT, and PET-CT (optional), based on the AJCC 8th edition TNM staging system. 4.The number of neoadjuvant treatment cycles is not limited. The treatment plans include: chemotherapy, chemotherapy + immunotherapy, and chemotherapy + targeted therapy. 5.After neoadjuvant therapy, after discussion by the MDT, radical surgery (R0 resection is expected) was deemed feasible, and robotic or laparoscopic radical total gastrectomy was performed. 6.The preoperative ECOG physical status score was 0/1. 7.Preoperative ASA score: I - III; 8.The clinical data are complete (including records of neoadjuvant therapy, surgical records, pathological reports, and follow-up data).
Exclusion criteria
Exclusion criteria: 1.It was confirmed during or after the operation to be in stage M1 (distant metastasis) or stage T4b. 2.There is a history of previous abdominal surgery (excluding laparoscopic cholecystectomy and appendectomy). 3.Having a history of other malignant tumors within the past 5 years; 4.Combined with severe dysfunction of the heart, lungs, liver and kidneys, unable to withstand surgery; 5.Gastric cancer with complications (bleeding, perforation, obstruction) requiring emergency surgery; 6.The clinical data is incomplete (key data is missing).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Early postoperative complications; | — |
Countries
China
Contacts
Public ContactYan Shi
The First Affiliated Hospital of Army Medical University
Outcome results
None listed